Home Protein Tyrosine Kinase VEGFR inhibitor - PDGFR inhibitor Vorolanib

research use only

Vorolanib VEGFR inhibitor

Cat.No.S6843

Vorolanib (X-82,CM082) is an oral, multikinase, dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) with antiangiogenic and antineoplastic activities.
Vorolanib VEGFR inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 439.4

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S684301 DMSO]89 mg/mL]false]Ethanol]5 mg/mL]false]Water]˂1 mg/mL]false Purity: 99.83%
99.83

Chemical Information, Storage & Stability

Molecular Weight 439.4 Formula

C23H26FN5O3

 Storage (From the date of receipt) 3 years -20°C powder
CAS No. 1013920-15-4 -- Storage of Stock Solutions

Synonyms X-82,CM082 Smiles CC1=C(NC(=C1C(=O)NC2CCN(C2)C(=O)N(C)C)C)C=C3C4=C(C=CC(=C4)F)NC3=O

Solubility

In vitro
Batch:

DMSO : 89 mg/mL (202.54 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 5 mg/mL

Water : ˂1 mg/mL

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
VEGFR [1]
PDGFR [1]
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04126668 Completed
Advanced Malignant Solid Tumors
AnewPharma
 December 19 2019 Phase 1
NCT03511222 Terminated
Solid Tumor|Hepatocellular Carcinoma|Gastric Cancer|Gastroesophageal Junction Adenocarcinoma
Washington University School of Medicine|Xcovery Holdings Inc.
 September 11 2018 Phase 1
NCT02577458 Unknown status
Renal Cell Carcinoma Recurrent
AnewPharma|Peking University Cancer Hospital & Institute
 September 2015 Phase 1
NCT02452385 Suspended
Age-Related Macular Degeneration
AnewPharma|West China Hospital
 March 2015 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Signaling Pathway Map